Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Protalix BioTherapeutics, Inc is a biotechnology business based in the US. Protalix BioTherapeutics shares (PLX) are listed on the NYSE MKT and all prices are listed in US Dollars. Protalix BioTherapeutics employs 196 staff and has a trailing 12-month revenue of around USD$61.2 million.
|Latest market close||USD$3.63|
|52-week range||USD$2.0362 - USD$4.87|
|50-day moving average||USD$3.6073|
|200-day moving average||USD$3.6283|
|Wall St. target price||USD$13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.174|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-1.89%|
|1 month (2020-12-16)||-5.22%|
|3 months (2020-10-16)||-0.27%|
|6 months (2020-07-16)||7.08%|
|1 year (2020-01-16)||3.63|
|2 years (2019-01-16)||811.83%|
|3 years (2018-01-16)||395.36%|
|5 years (2016-01-15)||342.68%|
Valuing Protalix BioTherapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Protalix BioTherapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Protalix BioTherapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.5 million.
The EBITDA is a measure of a Protalix BioTherapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$61.2 million|
|Operating margin TTM||3.39%|
|Gross profit TTM||USD$43.8 million|
|Return on assets TTM||2.05%|
|Return on equity TTM||0%|
|Market capitalisation||USD$119.3 million|
TTM: trailing 12 months
There are currently 283,425 Protalix BioTherapeutics shares held short by investors – that's known as Protalix BioTherapeutics's "short interest". This figure is 115.8% up from 131,336 last month.
There are a few different ways that this level of interest in shorting Protalix BioTherapeutics shares can be evaluated.
Protalix BioTherapeutics's "short interest ratio" (SIR) is the quantity of Protalix BioTherapeutics shares currently shorted divided by the average quantity of Protalix BioTherapeutics shares traded daily (recently around 168705.35714286). Protalix BioTherapeutics's SIR currently stands at 1.68. In other words for every 100,000 Protalix BioTherapeutics shares traded daily on the market, roughly 1680 shares are currently held short.
However Protalix BioTherapeutics's short interest can also be evaluated against the total number of Protalix BioTherapeutics shares, or, against the total number of tradable Protalix BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Protalix BioTherapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Protalix BioTherapeutics shares in existence, roughly 10 shares are currently held short) or 0.0086% of the tradable shares (for every 100,000 tradable Protalix BioTherapeutics shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Protalix BioTherapeutics.
Find out more about how you can short Protalix BioTherapeutics stock.
We're not expecting Protalix BioTherapeutics to pay a dividend over the next 12 months.
Protalix BioTherapeutics's shares were split on a 1:10 basis on 20 December 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Protalix BioTherapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Protalix BioTherapeutics shares which in turn could have impacted Protalix BioTherapeutics's share price.
Over the last 12 months, Protalix BioTherapeutics's shares have ranged in value from as little as $2.0362 up to $4.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Protalix BioTherapeutics's is 2.8787. This would suggest that Protalix BioTherapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.